James Crowley: ctDNA Origins, Cancer Biology and Clinical Study Needs
James Crowley, Professor of Medicine Emeritus at Brown University, shared a post on LinkedIn:
“Important information. But the biology here of where that increased ctDNA is coming from (primary or early Mets) is unknown.
As with colorectal cancer (CRC) ctDNA tests are extremely promising but further evaluation in larger cohorts of screen-relevant patients is warranted to confirm the basic performance characteristics of the blood test assay.
Concomitant clinical studies of future cases of Stage 1 cases that involve defined best practice adjuvant radiation, chemotherapy or immune checkpoints inhibition therapy must also be considered and conducted.
Finally, the basic cancer biology of cancer organoids from the primary tumour and sadly in uncured patients from first detectable metastases must be tested.
In particular, how each stage correlates with secretion of ctDNA in silico needs to be correlated with initial serum levels of ctDNA.”
More posts featuring James Crowley.
James P. Crowley is a Professor of Medicine Emeritus at Brown University and serves as a volunteer physician at the Rhode Island Free Clinic. He has held leadership positions in the medical community, including past President of the Rhode Island Medical Society and the last President of The Providence Medical Association.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023